Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2005

View Archived Issues

Antiangiogenic and anticancer properties of the PDGFR inhibitor CP-673451

Biota and Aerogen sign influenza development agreement

Altea Therapeutics' hydromorphone transdermal patch enters phase II

Miravant plans confirmatory phase III study for Photrex

Clinical trials with ixabepilone in prostate cancer

A meta-analysis confirms the benefits of atrasentan in HRPC

Apatone may be implicated clinically in the treatment of prostate cancer

ViroPharma and Wyeth discontinue development of HCV-086

Vical receives SBIR grant for CMV vaccine development

Cholate metal complexes exert cytotoxic and antiproliferative effects on tumor cells

CB1 antagonist prevents relapsing to heroin seeking in rats

Savient terminating phase II Prosaptide study

Viprinex set for phase III in the summer

La Jolla Pharmaceutical meets with FDA over Riquent approvability

TAK-715 is being tested in phase II trials for rheumatoid arthritis

MCHR1 antagonist shows notable selectivity and good PK profile

MNTX shows efficacy in the treatment of opioid-induced constipation

Iloprost increases the efficacy of bosentan therapy in PAH patients

Update on the therapeutic benefits of Remune(R) in HIV infection

Clarithromycin reported to increase the antiparkinsonian effects of cabergoline

Clinical evidence of the effects and safety of lapatinib in patients with urothelial tumors

CEP-1347 inhibits the c-Jun N-terminal kinase cascade to evoke apoptosis

Preclinical neuroprotective and cognitive-enhancing effects of EHT-0202

European approval for Zonegran

Ionix Pharmaceuticals described sodium channel blockers

Tachykinin receptor antagonists disclosed in a patent

CGRP receptor antagonists reported by Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...